Petr Protiva1, Swaroop Pendyala2, Celeste Nelson2, Leonard H Augenlicht3, Martin Lipkin4, Peter R Holt5. 1. Yale University and Veterans Affairs Connecticut Healthcare System, New Haven, CT; The Rockefeller University, New York, NY; 2. The Rockefeller University, New York, NY; 3. Albert Einstein College of Medicine, Bronx, NY; and. 4. Weill Cornell Medical College, New York, NY. 5. The Rockefeller University, New York, NY; petr.protiva@yale.edu.
Abstract
BACKGROUND: A high dietary calcium intake with adequate vitamin D status has been linked to lower colorectal cancer risk, but the mechanisms of these effects are poorly understood. OBJECTIVE: The objective of this study was to elucidate the effects of a Western-style diet (WD) and supplemental calcium and/or 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] on the colorectal mucosa. DESIGN: We conducted 2 crossover trials to define molecular pathways in the human colorectum altered by 1) a 4-wk WD supplemented with and without 2 g calcium carbonate/d and 2) a 4-wk WD supplemented with 1,25(OH)2D3 (0.5 μg/d) with or without 2 g calcium carbonate/d. The primary study endpoint was genome-wide gene expression in biopsy specimens of the rectosigmoid colonic mucosa. Serum and urinary calcium concentrations were also measured. RESULTS: Changes in urinary calcium accurately reflected calcium consumption. The WD induced modest upregulation of genes involved in inflammatory pathways, including interferon signaling, and calcium supplementation reversed these toward baseline. In contrast, supplementation of the WD with 1,25(OH)2D3 induced striking upregulation of genes involved in inflammation, immune response, extracellular matrix, and cell adhesion. Calcium supplementation largely abrogated these changes. CONCLUSIONS: Supplementing 1,25(OH)2D3 to a WD markedly upregulated genes in immune response and inflammation pathways, which were largely reversed by calcium supplementation. This study provides clinical trial evidence of global gene expression changes occurring in the human colorectum in response to calcium and 1,25(OH)2D3 intervention. One action of 1,25(OH)2D3 is to upregulate adaptive immunity. Calcium appears to modulate this effect, pointing to its biological interaction in the mucosa. This trial was registered at clinicaltrials.gov as NCT00298545 Trial protocol is available at http://clinicalstudies.rucares.org (protocol numbers PHO475 and PHO554).
RCT Entities:
BACKGROUND: A high dietary calcium intake with adequate vitamin D status has been linked to lower colorectal cancer risk, but the mechanisms of these effects are poorly understood. OBJECTIVE: The objective of this study was to elucidate the effects of a Western-style diet (WD) and supplemental calcium and/or 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] on the colorectal mucosa. DESIGN: We conducted 2 crossover trials to define molecular pathways in the human colorectum altered by 1) a 4-wk WD supplemented with and without 2 g calcium carbonate/d and 2) a 4-wk WD supplemented with 1,25(OH)2D3 (0.5 μg/d) with or without 2 g calcium carbonate/d. The primary study endpoint was genome-wide gene expression in biopsy specimens of the rectosigmoid colonic mucosa. Serum and urinary calcium concentrations were also measured. RESULTS: Changes in urinary calcium accurately reflected calcium consumption. The WD induced modest upregulation of genes involved in inflammatory pathways, including interferon signaling, and calcium supplementation reversed these toward baseline. In contrast, supplementation of the WD with 1,25(OH)2D3 induced striking upregulation of genes involved in inflammation, immune response, extracellular matrix, and cell adhesion. Calcium supplementation largely abrogated these changes. CONCLUSIONS: Supplementing 1,25(OH)2D3 to a WD markedly upregulated genes in immune response and inflammation pathways, which were largely reversed by calcium supplementation. This study provides clinical trial evidence of global gene expression changes occurring in the human colorectum in response to calcium and 1,25(OH)2D3 intervention. One action of 1,25(OH)2D3 is to upregulate adaptive immunity. Calcium appears to modulate this effect, pointing to its biological interaction in the mucosa. This trial was registered at clinicaltrials.gov as NCT00298545 Trial protocol is available at http://clinicalstudies.rucares.org (protocol numbers PHO475 and PHO554).
Authors: Maria S Barnes; Geraldine Horigan; Kevin D Cashman; Tom R Hill; L Kirsty Forsythe; Alice J Lucey; Emeir M McSorley; Mairead Kiely; Maxine P Bonham; Pamela J Magee; J J Strain; Julie M W Wallace Journal: J Nutr Date: 2011-01-26 Impact factor: 4.798
Authors: Myfanwy H Hopkins; Joy Owen; Thomas Ahearn; Veronika Fedirko; W Dana Flanders; Dean P Jones; Roberd M Bostick Journal: Cancer Prev Res (Phila) Date: 2011-06-30
Authors: Thomas U Ahearn; Marjorie L McCullough; W Dana Flanders; Qi Long; Eduard Sidelnikov; Veronika Fedirko; Carrie R Daniel; Robin E Rutherford; Aasma Shaukat; Roberd M Bostick Journal: Cancer Res Date: 2010-11-17 Impact factor: 12.701
Authors: Petr Protiva; Joel B Mason; Zhenhua Liu; Michael E Hopkins; Celeste Nelson; James R Marshall; Richard W Lambrecht; Swaroop Pendyala; Levy Kopelovich; Myungjin Kim; Steven H Kleinstein; Peter W Laird; Martin Lipkin; Peter R Holt Journal: Cancer Prev Res (Phila) Date: 2011-02-14
Authors: Petr Protiva; Heide S Cross; Michael E Hopkins; Enikö Kállay; Giovanna Bises; Eleanor Dreyhaupt; Leonard Augenlicht; Martin Lipkin; Martin Lesser; Elayne Livote; Peter R Holt Journal: Cancer Prev Res (Phila) Date: 2009-01
Authors: Harold L Newmark; Kan Yang; Naoto Kurihara; Kunhua Fan; Leonard H Augenlicht; Martin Lipkin Journal: Carcinogenesis Date: 2008-11-18 Impact factor: 4.944
Authors: Mazda Jenab; H Bas Bueno-de-Mesquita; Pietro Ferrari; Franzel J B van Duijnhoven; Teresa Norat; Tobias Pischon; Eugène H J M Jansen; Nadia Slimani; Graham Byrnes; Sabina Rinaldi; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sophie Morois; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Manuela M Bergmann; Antonia Trichopoulou; Gesthimani Misirli; Dimitrios Trichopoulos; Franco Berrino; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Martine M Ros; Carla H van Gils; Petra H Peeters; Magritt Brustad; Eiliv Lund; María-José Tormo; Eva Ardanaz; Laudina Rodríguez; Maria-José Sánchez; Miren Dorronsoro; Carlos A Gonzalez; Göran Hallmans; Richard Palmqvist; Andrew Roddam; Timothy J Key; Kay-Tee Khaw; Philippe Autier; Pierre Hainaut; Elio Riboli Journal: BMJ Date: 2010-01-21
Authors: James P Blackmur; Peter G Vaughan-Shaw; Kevin Donnelly; Bradley T Harris; Victoria Svinti; Anna-Maria Ochocka-Fox; Paz Freile; Marion Walker; Toby Gurran; Stuart Reid; Colin A Semple; Farhat V N Din; Maria Timofeeva; Malcolm G Dunlop; Susan M Farrington Journal: Front Genet Date: 2022-01-04 Impact factor: 4.599
Authors: P G Vaughan-Shaw; G Grimes; J P Blackmur; M Timofeeva; M Walker; L Y Ooi; Victoria Svinti; Kevin Donnelly; F V N Din; S M Farrington; M G Dunlop Journal: BMC Med Date: 2021-08-03 Impact factor: 8.775